Association of dual-pathway antithrombotic therapy with primary patency after iliofemoral venous stenting: a multicenter cohort study
Can Chen, Zhenyu Guo, Jian Tang, Zhiqing Wei, Guowei Liu, Zhenyu Shi, Daqiao Guo, Weiguo Fu, Qianzhou Lv, Baolei Guo · 2026
Read Association of dual-pathway antithrombotic therapy with primary patency after iliofemoral venous stenting: a multicenter cohort study by Can Chen, Zhenyu Guo, Jian Tang, Zhiqing Wei, Guowei Liu, Zhenyu Shi, Daqiao Guo, Weiguo Fu, Qianzhou Lv, Baolei Guo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13675916.txt.
Description
Can Chen and a large team of co-authors ask which blood-thinner strategy keeps leg vein stents open, in this 2026 study. After a stent is placed in the iliofemoral vein, doctors must choose between an anticoagulant alone or that drug plus an antiplatelet agent, the dual-pathway option. Practice varies because the best answer is unsettled.
The study followed two hundred forty-seven patients at several centers who received stents between 2019 and 2024. Overall, about ninety-one percent of stents stayed open, and the two strategies tied: patency did not differ between the groups. In the subgroup whose veins were scarred by past clots, though, the single-drug group lost patency more often than the dual group. The authors treat that signal as exploratory and call for a properly powered randomized trial with longer follow-up and safety checks.
Catalog record
| CREATOR | Can Chen, Zhenyu Guo, Jian Tang, Zhiqing Wei, Guowei Liu, Zhenyu Shi, Daqiao Guo, Weiguo Fu, Qianzhou Lv, Baolei Guo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |